Vasculitis Archives

Vasculitis

Case Study Reports First Known Case of Neutrophilic Arterial Vasculitis in COVID-19

By

Emily Pond

October 19, 2020

Authors of this case study reported the first case of neutrophilic arterial vasculitis in COVID-19.

Vasculitis

FDA to Review Avacopan for ANCA-Associated Vasculitis

By

Brian Park, PharmD

September 23, 2020

Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.

Vasculitis

Specimen Length, Number of Sections Linked to Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis

By

Amit Akirov, MD

August 25, 2020

Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.

General Rheumatology

Iloprost May Be Useful in the Treatment of COVID-19 Vasculopathy

By

Meghna Rao

July 27, 2020

Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.

Vasculitis

Avacopan NDA Submitted for ANCA-Associated Vasculitis

By

Brian Park, PharmD

July 16, 2020

ChemoCentryx, Inc has submitted a NDA to the FDA for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Vasculitis

Long-Term Rituximab Linked to Reduced Incidence of ANCA-Associated Vasculitis

June 12, 2020

Extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis relapse in GPA or MPA.

EULAR 2020 Coverage

Avacopan May Be Safe, Efficacious, and Superior to Other Treatments in ANCA-Associated Vasculitis

By

Alyssa Capel

June 5, 2020

Researchers evaluated the efficacy and safety of avacopan for the treatment of ANCA-associated vasculitis.

doctor using ipad, telemedicine, telehealth

General Rheumatology

The Autoimmune COVID-19 Project: A Patient-Centered Initiative

By

Meghna Rao

May 29, 2020

Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.